Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 91 clinical trials
Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma (QUAD01)

Patients with unresectable or metastatic BRAF-mutant melanoma high-risk patients will be given 450 mg orally (PO) daily (QD) plus binimetinib 45 mg PO twice daily (BID) together with nivolumab administered intravenously (IV) at 3mg/kg and ipilimumab administered IV at 1 mg/kg every 3 weeks for 4 doses, followed by nivolumab …

cancer
cytotoxic t-lymphocyte antigen 4
BRAF
nivolumab
braf inhibitor
  • 5 views
  • 13 Apr, 2022
  • 1 location
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab +Dendritic Cells in NSCLC

A randomized phase II clinical trial of SBRT and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in NSCLC

metastasis
pembrolizumab
cancer chemotherapy
endobronchial ultrasound
  • 0 views
  • 26 Jan, 2021
  • 2 locations
A Personalized Neoantigen Cancer Vaccine in Treatment Na ve Asymptomatic Patients With IGHV Unmutated CLL.

This research study is studying a novel type of CLL vaccine as a possible treatment for chronic lymphocytic leukemia (CLL) The names of the study interventions involved in this study are: Personalized NeoAntigen Vaccine Poly-ICLC Cyclophosphamide Pembrolizumab

  • 0 views
  • 28 Sep, 2021
  • 1 location
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (ABC-X)

This is a phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with asymptomatic, untreated melanoma brain metastases.

  • 16 views
  • 26 Jul, 2022
  • 5 locations
Multicenter Study of Safety and Efficacy of Prolgolimab in Patients With Advanced Melanoma in Routine Clinical Practice

Describe the safety, tolerability, efficacy and approaches to prescribing prolgolimab in the standard dosing regimen of 1 mg / kg every 2 weeks in patients with advanced melanoma in routine

  • 0 views
  • 25 Nov, 2021
  • 1 location
Impact of Immunotherapy on the Sperm Count of Patients With Cancer

for the treatment of advanced melanoma. On the other hand, PD-1 is another receptor for the immune control point, and its ligands, the programmed cell death ligand 1 (PD-L1) and PD-L2, also

  • 0 views
  • 25 Jan, 2021
  • 1 location
The Registry of Oncology Outcomes Associated With Testing and Treatment

This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. It will also create reusable infrastructure to allow creation or affiliation with many additional RWD/RWE efforts both prospective and …

diagnostic procedures
lab tests
primary cancer
  • 0 views
  • 22 Oct, 2021
  • 1 location
Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma

Screen and recruitment: patients will be screened based on their prior history and intention to initiate treatment with an immune checkpoint inhibitor. Study phase: Collection of baseline demographic data, prior disease history, nature of ICI therapy, outcome data of ICI therapy (treatment disposition, toxicity, tumor response and survival). Collection of …

advanced melanoma
metastasis
  • 24 views
  • 27 Jan, 2021
  • 2 locations
Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma

This is a non-therapeutic study assessing peripheral T cell determinants of response and resistance to immunotherapy in patients with advanced melanoma.The hypothesis is that systemic T cells traffic into the tumor microenvironment (TME) can predict response and resistance to immunotherapy. These systemic tumor directed T cells can be defined by …

cancer
pembrolizumab
advanced melanoma
metastatic melanoma
measurable disease
  • 0 views
  • 24 Nov, 2021
  • 1 location
Predicting Response to Immunotherapy for Melanoma With Gut Microbiome and Metabolomics (PRIMM)

This study will investigate the effects of gut microbiome diversity (richness in terms of many bacterial species in the gut) on responses and side effects of immunotherapy in advanced melanoma

advanced melanoma
cancer
  • 7 views
  • 13 Feb, 2022
  • 5 locations